Top 10 Emerging Medtech Companies

LifeBridge 10000: Revolutionizing The Treatment Of Metastatic Cancers

Top 10 Emerging Medtech Companies – 2021

With the rise of life expectancy worldwide and the ageing of populations, the transformative power of technology is being felt quite substantially in the healthcare sector.

Automation, for instance, is enhancing the healthcare experience for patients and providers by providing more efficient ways to expand care capacity while meeting the high demand for virtual care. Automation is also lightening the load on the administrative front by converting paperwork to digital data, streamlined report generation, and the general management of patient records. The technology is also reducing costs associated with healthcare management thanks to its efficiency, accuracy, and scalability.

Besides, robots in the medical field are transforming how surgeries are performed, streamlining supply delivery and disinfection, and freeing up time for providers to engage with patients. In addition, robotics enable a high level of patient care, efficient processes in clinical settings, and a safe environment for both patients and health workers.

At this juncture, there is a variety of emerging medtech companies and medtech providers that are entering the market to cater to the different needs of enterprises. To help them choose the solution that best fits their requirement, MedTech Outlook has compiled lists of the top established medtech providers and emerging medtech companies. Besides, the magazine also comprises insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for aspiring CIOs.

We present to you MedTech Outlook’s, “Top 10 Emerging Medtech Companies – 2021.”

Top 10 Emerging Medtech Companies – 2021

Top 10 Emerging Medtech Companies

LifeBridge 10000

Transforming metastatic cancer from a terminal prognosis into a manageable disease like diabetes

Transverse Medical

Transverse Medical is driven by the mission to minimize or eliminate the risk of stroke. The company’s first-in-human clinical study verified that the major challenge for a highly successful CEPD was that the design must be adaptable to a wide variety of aortic arch anatomies encountered during TAVR procedures while simultaneously providing full coverage of the great arch vessels. That’s where the development of the next generation POINT-GUARD™ implements a proprietary asymmetric 3D design, coupled with a novel approach and scientific use of flat-nitinol.

Alleviant Medical

Alleviant Medical is a medical device company developing potential therapies for congestive heart failure. The Alleviant System is a novel transcatheter device for the creation of a therapeutic interatrial shunt without a permanent cardiac implant. The company has developed a transcatheter technology intended to decompress the left atrium without a permanent cardiac implant or open surgery. The procedure is designed to be performed under fluoroscopy (x-ray) and ultrasound guidance using a minimally-invasive approach and leverages standard interventional cardiology techniques. The company’s mission is to alleviate the significant clinical and economic burden of heart failure and to improve the lives of millions of patients suffering from this debilitating disease. Alleviant Medical’s investment partners include Vensana Capital, Broadview and Longview Ventures, TMC Venture Fund, S3 Ventures and an undisclosed strategic investor.

Atia Vision

Atia Vision is a portfolio company of Shifamed, LLC, a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives. The team at Atia Vision is committed to improving patient outcomes by developing a safe and controllable presbyopia correcting IOL that aims to restore the full range of functional vision in cataract patients, the largest segment of the ophthalmology market.

CairnSurgical

CairnSurgical, Inc. is a clinical stage medical device company developing patient-specific surgical guides using patient imaging data and state-of-the-art 3D printing technologies. CairnSurgical’s Breast Cancer Locator System enables precise tumor localization and excision, and has been tested in both single-arm and randomized clinical trials. The Breast Cancer Locator is considered an investigational device in the U.S. and is limited by U.S. law to investigational use only.

Cardialen

Established in 2008, Cardialen, Inc., set out to develop an implantable defibrillation therapy using low-electrical energy designed to more gently restore normal heart rhythm and potentially avoid the negative side-effects of current therapies. Its MultiPulse™ Therapy (MPT) is currently being studied in an FDA-approved early feasibility IDE clinical trial exploring how a sequence of low-energy pulses timed to stop abnormal heart rhythms may restore normal heart rhythm using less energy than current high-energy shocks.

EBR Systems

EBR Systems, Inc. is driven to deliver superior treatment for millions of patients suffering from cardiac rhythm diseases by developing safe, clinically superior, cost-effective and reliable therapies using wireless cardiac stimulation. The company’s initial product, the WiSE™ CRT System, is a first-of-its-kind medical device developed to overcome the limitations of traditional Cardiac Resynchronization Therapy (CRT) in heart failure patients by eliminating the need for a lead to the heart’s left ventricle and the associated complications of that lead.

Neomedic

Neomedic provides the medical field with the best surgical options for Urinary Incontinence and Pelvic Organ Prolapse treatment. Neomedic International sells through its distribution network to more than 40 countries. The quality of Neomedic products and customer’s satisfaction has established the company as the worldwide reference for pelvic floor solutions.

Second Heart Assist

With its novel aortic stent pump technologies, Second Heartis enhancing the lives of millions who suffer from chronic HF worldwide. Second Heart Assist objectives are to improve the quality of life by reducing the heart’s work-load and improve perfusion. The enhancement of renal function reduces risks associated with toxic contrasts used in percutaneous catheterization interventions (High Risk PCI).

Valcare Medical

Valcare Medical is dedicated to providing innovative minimally-invasive technologies for the treatment of mitral and tricuspid regurgitation. Its product line includes solutions for the repair and replacement of the mitral valve as well as the repair of the tricuspid valve. Its breakthrough mitral valve treatment platform is based on a D-shaped ring which serves both as a docking station for Valcare’s unique replacement prosthesis, and as a highly-effective tool for mitral annulus repair. The company's mitral repair and replacement systems as well as its tricuspid repair solution establish Valcare Medical as a leader in valve care, a responsibility it very much takes to heart.